An analysis of a randomized clinical trial found patients with cardiovascular disease and type 2 diabetes who received sitagliptin had similar rates of heart failure or other cardiovascular complications compared with a placebo group.

A clinical risk score helped predict the risk of ischemic stroke, thromboembolism and death in patients with heart failure, according to an analysis of three nationwide registries in Denmark. However, the researchers noted the predictive accuracy was modest.

Only 10 percent of patients with heart failure were referred to cardiac rehabilitation after hospital discharge between 2005 and 2014, according to a database analysis. Although the referral rates were higher in recent years, the researchers noted that they expected more people to be told to attend cardiac rehabilitation sessions.

A large percentage of patients hospitalized for heart failure at Yale-New Haven hospital had symptoms such as anxiety and pain that are typically not associated with the condition, according to a prospective study. The researchers also found that patients often did not have improvements in symptom severity after getting discharged.

After a mean follow-up of 13 years, Swedish men who had moderate levels of physical activity had a lower risk of heart failure compared with those who had high or low activity levels, according to a population-based cohort study.

The FDA warned of serious adverse events associated with certain left ventricular assist devices (LVADs), which are implanted in patients with advanced heart failure.

Since former Vice President Dick Cheney had a left ventricular assist device (LVAD) implanted in 2012, general interest in the devices have increased and social media sites have included more information on them.

Bellerophon Therapeutics announced on July 27 that top-line results from a clinical trial found its investigational cardiac implantable device did not improve outcomes compared with placebo.